retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide (Eli Lilly's triple GLP-1 PDB-101: Molecule of the Month:
Description
18 12% GLP-1
By targeting all three, retatrutide seeks to reduce fat, preserve muscle, and assist blood sugar control
Drug interactions : No licensed interaction data exist for retatrutide
Long-term observations of glucose tolerance in thyrotoxic patients
